Lewes, DE -- (ReleaseWire) -- 03/18/2014 -- The epilepsy therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.7%.
According to latest report, China and India are expected to show the fastest growth over the forecast period, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%.
Senior Analyst of this report, says: “With a high epilepsy prevalence, China and India have large treatment populations, which are expected to increase further in the future due to better healthcare access and an improvement in treatment gaps.”
GBI Research states that the epilepsy sector is still dominated by older generation Anti-Epileptic Drugs (AEDs), such as carbamazepine, valproate, oxcarbazepine and phenytoin, which account for a combined share of over 60% of the APAC region’s market. Historically, these AEDs have had poor safety and tolerability profiles.
However, second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets.
Analyst concludes: “Approximately 20 to 30% of epilepsy patients fail to respond to treatment with existing AEDs. This population forms a sizeable chunk of the market, which is promising for new entrants. Both Fycompa and Trobalt have the potential to address refractory epilepsy patient needs when launched in their respective markets.”
This report provides analysis of the epilepsy market within the Asia-Pacific region covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by team of industry experts.
For report pricing and TOC please visit: http://www.marketresearchreports.com/gbi-research/epilepsy-therapeutics-asia-pacific-markets-2019-treatment-options-enhanced-novel-next
Browse other reports in therapeutic section: http://www.marketresearchreports.com/therapeutic
Current offers are going on pharma reports visit this link for more information: http://www.marketresearchreports.com/special-offers
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
Follow us on Twitter: https://twitter.com/MyMarketReports